Mawer Investment Management Ltd. has added 543,460 shares of $BSX to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2026 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $BSX.
BOSTON SCIENTIFIC Hedge Fund Activity
We have seen 799 institutional investors add shares of BOSTON SCIENTIFIC stock to their portfolio, and 909 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 32,976,583 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $3,144,317,189
- BLACKROCK, INC. removed 9,188,624 shares (-6.3%) from their portfolio in Q4 2025, for an estimated $876,135,298
- BANK OF AMERICA CORP /DE/ removed 8,753,856 shares (-25.8%) from their portfolio in Q4 2025, for an estimated $834,680,169
- FISHER ASSET MANAGEMENT, LLC removed 8,687,613 shares (-95.1%) from their portfolio in Q1 2026, for an estimated $537,850,120
- MARSHALL WACE, LLP removed 6,841,803 shares (-69.8%) from their portfolio in Q4 2025, for an estimated $652,365,916
- ASSENAGON ASSET MANAGEMENT S.A. added 5,751,760 shares (+133.6%) to their portfolio in Q1 2026, for an estimated $356,091,461
- WELLINGTON MANAGEMENT GROUP LLP removed 4,944,352 shares (-33.7%) from their portfolio in Q4 2025, for an estimated $471,443,963
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
BOSTON SCIENTIFIC Insider Trading Activity
BOSTON SCIENTIFIC insiders have traded $BSX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 2 sales selling 160,901 shares for an estimated $15,043,394.
- ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) sold 17,313 shares for an estimated $1,758,188
- ELLEN M ZANE sold 12,891 shares for an estimated $1,266,977
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
BOSTON SCIENTIFIC Government Contracts
We have seen $23,545,120 of award payments to $BSX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION: $1,260,000
- Y90 GLASS MICROSPHERES: $1,227,000
- Y90 THERASPHERE: $1,155,000
- VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS: $954,240
- THERASPHERE YTTIRUM-90 (Y-90) GLASS: $833,910
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BOSTON SCIENTIFIC Congressional Stock Trading
Members of Congress have traded $BSX stock 6 times in the past 6 months. Of those trades, 4 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 3 purchases worth up to $45,000 on 02/10, 01/30, 11/18 and 1 sale worth up to $15,000 on 12/24.
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 12/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
BOSTON SCIENTIFIC Analyst Ratings
Wall Street analysts have issued reports on $BSX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/05/2026
- Truist Securities issued a "Buy" rating on 02/05/2026
- BTIG issued a "Buy" rating on 02/04/2026
- RBC Capital issued a "Outperform" rating on 12/17/2025
To track analyst ratings and price targets for BOSTON SCIENTIFIC, check out Quiver Quantitative's $BSX forecast page.
BOSTON SCIENTIFIC Price Targets
Multiple analysts have issued price targets for $BSX recently. We have seen 20 analysts offer price targets for $BSX in the last 6 months, with a median target of $87.5.
Here are some recent targets:
- David Roman from Goldman Sachs set a target price of $84.0 on 04/23/2026
- Mike Matson from Needham set a target price of $77.0 on 04/23/2026
- Richard Newitter from Truist Securities set a target price of $85.0 on 04/23/2026
- David Rescott from Baird set a target price of $78.0 on 04/23/2026
- Larry Biegelsen from Wells Fargo set a target price of $75.0 on 04/23/2026
- Matt Miksic from Barclays set a target price of $96.0 on 04/23/2026
- Vijay Kumar from Evercore ISI Group set a target price of $78.0 on 04/23/2026
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $BSX ticker page for more data.
